FP011 / FAPON - LARVOL DELTA

Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025 (PRNewswire) - "Fapon Biopharma...is pleased to announce its participation in the BIO International Convention 2025 (BIO 2025), taking place June 16-19 in Boston Convention & Exhibition Center. The company will exhibit at Booth #1851, presenting its differentiated pipeline, including the flagship Phase 1 immunocytokine FP008, a portfolio of promising early-stage candidates for oncology and autoimmune diseases, and its suite of proprietary technology platforms, while actively seeking global partnerships...The company will also feature promising preclinical candidates targeting oncology (FP010, FP011, FPE021) and autoimmune diseases (FPE022, FPE024), highlighting its expanding research capabilities."

P1 data • Preclinical • Immunology • Solid Tumor

FP011, A tri-specific immune checkpoint inhibitor targeting PD-1 × TIGIT × PVRIG for cancer immunotherapy (AACR 2025) - "In an antigen-specific (CMV) T cell activation assay, in which T cells were induced to exhaustion after long-term stimulation with CMV antigens, FP011 also induced a more significant degree of T cell activation than what bi-specific antibodies, pembrolizumab and the combination of anti-PD-1, anti-PVRIG and anti-TIGIT monoclonal antibodies could do. In a PBMC-engrafted NOD-dKO-A375 mice model, FP011 inhibited tumor growth (93%, P < 0.0001) in a way significantly better than anti-PD-1 antibody (39.45%, P = 0.0627), the combination of anti-PD1, anti-PVRIG and anti-TIGIT antibodies (90% P < 0.0001), and another tri-specific positive control (66.18%, P = 0.0007). The inhibition of tumor growth was associated with an increase of tumor-infiltrating T cells following the FP011 treatment.In conclusion, these data provide insight into the efficacy of FP011, both in vitro and in vivo, which indicates that targeting three immune checkpoints simultaneously can synergistically..."

Checkpoint inhibition • Trispecific • Oncology • TIGIT